Vyas Paresh, Appelbaum Frederick R, Craddock Charles
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.
Biol Blood Marrow Transplant. 2015 Jan;21(1):8-15. doi: 10.1016/j.bbmt.2014.10.026. Epub 2014 Nov 13.
Allogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse.
异基因干细胞移植在成人急性髓系白血病（AML）的治疗中已成为一种越来越重要的治疗选择。治疗失败的主要原因仍然是疾病复发和治疗毒性。在本综述中，维亚斯博士概述了近期关于确定与AML治疗失败相关分子因素的重要数据。他还指出了白血病干细胞生物学在决定AML治疗反应和复发风险方面日益凸显的重要性。阿佩尔鲍姆博士讨论了清髓性和减低强度预处理方案在设计和实施方面的进展，重点介绍了有可能改善治疗结果的新策略。克拉多克博士讨论了旨在降低疾病复发风险的新型预处理方案和移植后策略的发展情况。
